
BioLineRx and Hemispherian report positive cancer data
- BioLineRx and Hemispherian announced strong preclinical synergy combining oncology candidate GLIX1 with the PARP inhibitor olaparib.
- The combined low-dose therapeutic regimen achieved localized tumor reduction comparable to standard platinum-based cisplatin treatments.
- The development partners plan to add an expansion arm targeting ovarian cancer to their active Phase 1/2a clinical infrastructure.
BioLineRx (NASDAQ:BLRX) and Hemispherian reported positive preclinical data from a patient-derived ovarian cancer xenograft model showing a strong therapeutic synergy between its small-molecule candidate GLIX1 and the approved PARP inhibitor olaparib.
The low-dose combination regimen achieved substantially improved anti-tumor efficacy compared to standard control groups and independent monotherapies without introducing overlapping toxicity penalties.
"The pronounced synergy observed with olaparib indicates that GLIX1 could become a valuable therapeutic option for patients facing difficult-to-treat gynecological malignancies," the company stated in its research directory.
The robust tumor reduction markers matched the therapeutic baseline established by heavy chemotherapy agent cisplatin while preserving a much cleaner physiological tolerability profile in the evaluated models.
Following the announcement, BioLineRx's share price was down at $2.74.
The operational partners intend to leverage these positive laboratory findings to formally append a dedicated ovarian cancer patient cohort to their ongoing Phase 1/2a clinical study.
The primary human trial framework is concurrently examining the metabolic mechanisms of the therapeutic compound inside advanced glioblastoma multiforme brain tumor clinical settings.
More from United States
Guardforce AI sets 1-for-40 share consolidation
VisionWave signs $11 million minerals platform deal
Stocks slide as AI selloff deepens, Asia faces worst week since 2020
InPost acquisition completed as consortium takes full ownership
RLX Technology revenue rises 69.7% in Q3
Oil prices rise as Middle East supply risks return